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Introduction
Rheumatologists face unique challenges in discriminating
between rheumatologic and nonrheumatologic disorders
with similar manifestations and in discriminating among
rheumatologic disorders with shared features. The major-
ity of rheumatic diseases are multisystem disorders with
poorly understood etiology; they tend to be heterogeneous
in their presentation, course, and outcome and do not
have a single clinical, laboratory, pathologic, or radiologic
feature that could serve as a “gold standard” in support of
diagnosis and/or classification. Thus, the development of
criteria for use in routine clinical care and in clinical
research has been an important focus in rheumatology. An
improved understanding of disease pathogenesis and the
availability of new diagnostic tools have led to a reexami-
nation of the existing classification and diagnostic criteria;
updated classification criteria for some diseases have been
endorsed recently (1,2).
The American College of Rheumatology (ACR) Subcom-
mittee on Classification and Response Criteria is responsi-
ble for guiding the development and validation of new
classification and response criteria that are eventually con-
sidered for endorsement by the ACR. This responsibility
includes reviewing proposals for the development of new
criteria sets and providing the ACR leadership with recom-
mendations for the development and approval of new clas-
sification and response criteria sets (1,3–5). Members of
the Subcommittee previously offered recommendations
for updating the standards for considering classification
and response criteria (6). That prior work provided details
about the rationale for the position of the ACR regarding
classification criteria, but clarification regarding the issue
of diagnostic criteria was lacking. Indeed, in 2010 the ACR
endorsed preliminary diagnostic criteria for fibromyalgia
(7), which prompted discussions about whether the Sub-
committee should also support the development and ACR
endorsement of diagnostic criteria, in addition to that of
classification and response criteria.
The primary objectives of this current article, by former
and current members of the Subcommittee on Classifica-
tion and Response Criteria, are to compare diagnostic and
classification criteria, using specific examples from the
published literature, and to clarify the ACR’s position on
both types of criteria (Table 1).
Diagnostic criteria
Diagnosis may be defined as determination of the cause or
nature of an illness by evaluating the signs, symptoms, and
results of supportive tests in an individual patient. Diagnos-
tic criteria are a set of signs, symptoms, and tests for use in
routine clinical care to guide the care of individual patients.
Supported by the American College of Rheumatology Classi-
fication and Response Criteria Subcommittee of the Committee
onQuality of Care.
1Rohit Aggarwal, MD, MS: University of Pittsburgh,
Pittsburgh, Pennsylvania; 2Sarah Ringold, MD, MS: Seattle
Children’s Hospital, Seattle, Washington; 3Dinesh Khanna,
MD, MS: University of Michigan, Ann Arbor; 4Tuhina Neogi,
MD, PhD, FRCPC, David Felson,MD: BostonUniversity School
of Medicine, Boston, Massachusetts; 5Sindhu R. Johnson, MD,
PhD: Toronto Western Hospital, Mount Sinai Hospital, and
University of Toronto, Toronto, Ontario, Canada; 6AmyMiller:
American College of Rheumatology, Atlanta, Georgia;
7Hermine I. Brunner, MD, MSc: Cincinnati Children’s Hospi-
tal and Medical Center, Cincinnati, Ohio; 8Rikke Ogawa,
MLIS: University of California, Los Angeles; 9Alexis Ogdie,
MD,MSCE:University of Pennsylvania, Philadelphia; 10Daniel
Aletaha,MD,MSc:MedicalUniversity of Vienna, Vienna,Aus-
tria; 11Brian M. Feldman, MD, MSc, FRCPC: Toronto Western
and Mount Sinai Hospitals, The Hospital for Sick Children,
andUniversity of Toronto, Toronto, Ontario, Canada.
Dr. Khanna has received consultant fees, speaking fees, and/
or honoraria (less than $10,000 each) from Actelion, Bayer,
Biogene, Idec, BMS, Cigna, Genentech/Roche, Intermune,
Merck, Sanofi-Aventis, and Genzyme. Dr. Felson has received
consultant fees, speaking fees, and/or honoraria (less than
$10,000) from Zimmer Knee Creations.
Address correspondence to Rohit Aggarwal, MD, MS,
Assistant Professor of Medicine, University of Pittsburgh,
3601 5th Avenue, Suite 2B, Pittsburgh, PA 15217. E-mail:
aggarwalr@upmc.edu.
Submitted for publication December 30, 2013; accepted
in revised form March 10, 2015.
891
Diagnostic criteria are generally broad and must
reflect the different features of a disease (heterogeneity),
with a goal of accurately identifying as many individu-
als with the condition as possible. Given this complex-
ity, the development and validation of diagnostic
criteria can be quite challenging. The Diagnostic and
Statistical Manual of Mental Disorders (DSM) is likely
the best-known example of diagnostic criteria. Its initial
development was prompted by the observation of ex-
tremely poor agreement among providers regarding psy-
chiatric diagnoses. There are only a few validated
diagnostic criteria in rheumatology, and clinicians com-
monly establish a diagnosis based on a subjective com-
bination of clinical signs/symptoms, results of available
clinical tests, and knowledge about epidemiology in
their geographic area.
Table 1. Summary of the key points*
Background question Should ACR support the development and endorsement of diagnostic criteria?
Objective 1. To compare diagnostic and classification criteria
2. To clarify the ACR’s position on ACR endorsement of diagnostic criteria
Methods Systematic review of literature, recommendation of ACR Classification and Response Criteria
Subcommittee, and subsequent ACR Quality of Care Committee and ACR Board of Directors approval
Results Classification Criteria Diagnostic Criteria
Classification criteria are standardized
definitions that are primarily intended to enable
clinical studies to have uniform cohorts for
research
Diagnostic criteria are a set of signs,
symptoms, and tests developed for use in
routine clinical care to guide the care of
individual patients
Need to define (relatively) homogenous group
that can be compared across studies and
geographic regions
Need to be broad and must reflect the all
possible different features and severity of a
disease (heterogeneity)
Very high specificity is required, even if some
loss in sensitivity
Both specificity and sensitivity need to be
very high, approaching 100%, which is difficult
to achieve
Single universal classification criteria can be
applied to different geographical regions, race
and ethnicities
Single universal diagnostic criteria cannot be
used for making diagnosis due to different
disease prevalence in different geographic areas,
race and ethnicities
Classification criteria are possible for disease
with and without true “gold standards” (e.g.,
MSU crystals in gout)
Diagnostic criteria are possible for disease
with a true “gold standard” like MSU crystals
in gout. For such diseases, the classification and
diagnostic criteria can be very similar. For
diseases without gold standard, development of
diagnostic criteria poses significant challenges
Differences in resources and feasibility has
limited effect on classification criteria
Differences in resources and feasibility
significantly effect development of diagnostic
criteria
Classification criteria are for research, and
therefore, should have no or little impact on
billing and reimbursement
Diagnostic criteria are for diagnosis, and
therefore, have implications for billing and
reimbursement
Classification criteria have no treatment
implications for patients
Diagnostic criteria have treatment
implications for patients
Health care priorities of different geographical
areas do not influence classification criteria
Health care priorities of different geographic
areas may influence diagnostic criteria
Classification of a disease can be
accomplished by a set of criteria with
reasonable sensitivity and specificity
Diagnosis is a complex multi-step process by
a physician, which is difficult to accomplish
with a single set of criteria
ACR recommendation Given the difficulty in establishing a uniform diagnostic criteria as noted above, the ACR will only
provide approval for classification criteria and will no longer consider funding or endorsement of
diagnostic criteria
* ACR 5 American College of Rheumatology; MSU 5 monosodium urate.
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Classification criteria
Classification criteria are standardized definitions that are
primarily intended to create well-defined, relatively homo-
geneous cohorts of patients for clinical research; they are
not intended to capture the entire universe of possible
patients but rather to capture the majority of patients who
share key features of the condition. Hence, the goal of clas-
sification differs from the intent of diagnostic criteria. Vali-
dated classification criteria are considered critical to the
interpretation of study findings and comparisons of results
between studies. Despite facilitating the comparison of
study results, classification criteria have the potential to
restrict the external validity of studies, because interven-
tions may perform differently in study participants who
fulfill classification criteria for a disease than in the broader
group of patients in whom the same disease was diagnosed
(i.e., those who share only some of the disease manifesta-
tions considered in the classification criteria).
Although classification criteria may provide some frame-
work to aid in diagnosis and are frequently used this way
in teaching, these criteria traditionally have high specific-
ity (defined as the proportion of patients who are known
not to have the disease who will test negative for it), which
generally comes at the expense of somewhat lower sensitiv-
ity (defined as the proportion of patients who are known to
have the disease and who will test positive for it). Conse-
quently, few individuals are incorrectly labeled as having a
disease (false positives), but a proportion of those with the
disease diagnosis may be “missed,” i.e., labeled as not hav-
ing the disease based on the classification criteria (false
negatives). This may make classification criteria inappro-
priate for use in routine clinical care (8).
Continuum of diagnosis and classification
Although diagnostic criteria may be different from classifi-
cation criteria, at least with regard to their intended pur-
pose, in reality they represent 2 ends of a continuum (9).
The “distance” between diagnostic and classification crite-
ria on this continuum depends on various factors, includ-
ing disease prevalence, geographic area, and prevalence of
“mimickers,” among others. When the etiology of a dis-
ease is well defined (as in gout and Lyme disease), diag-
nostic and classification criteria may be very similar and
can be used interchangeably. If sufficient internal and
external validity for diagnosis is demonstrated in a given
population, classification criteria can be diagnostic. In
theory, a diagnosis applies classification criteria to an indi-
vidual patient (9). Therefore, when classification criteria
have perfect (100%) sensitivity and specificity, classifica-
tion and diagnostic criteria are synonymous and would
correctly identify every single individual case (10). How-
ever, because disease features typically are not identical
among patients with a given disease, classification criteria
are not 100% accurate, thus leaving a certain proportion
of patients misclassified. Because of this possibility of mis-
classification, meeting classification criteria is not equi-
valent to carrying a given diagnosis. Only physicians
considering features of an individual patient, beyond those
represented in the classification criteria, in addition to
extraneous factors (such as the local prevalence of condi-
tions that are included in the differential diagnosis) can
establish a diagnosis for an individual patient.
Due to the lack of gold standards in the field of rheuma-
tology, any criteria (classification or diagnostic) are difficult
to establish. As detailed below, compared with classifica-
tion criteria, an array of factors pose greater challenges and
clinical implications for the development and validation of
diagnostic criteria. Even in those situations in which diag-
nostic criteria can be established, the question remains as
to whether the ACR and/or other international organiza-
tions should endorse a single set of diagnostic criteria.
Literature review
A systematic search of articles addressing classification
and/or diagnostic criteria for the rheumatic diseases was
performed by an experienced librarian (RO), considering the
PubMed database (1940–2011) and the Cochrane Central
Register of Controlled Trials database (from 1996 to 2011). In
combining the search terms for “Diagnosis AND Classifica-
tion AND Rheumatic Disease AND Methodology,” 3,825
citations from PubMed and 88 from the Cochrane database
were identified. Two reviewers (RA and SR) independently
screened the titles and abstracts of articles for relevance to
classification and diagnostic criteria in rheumatic diseases.
Abstracts were screened to identify articles that defined,
updated, addressed, reviewed, or commented on methodo-
logic aspects of classification or diagnostic criteria for the
rheumatic diseases. Screening of titles and abstracts exclu-
ded 3,681 articles, leaving 232 articles for detailed review.
This led to the identification of 97 articles that were deemed
relevant for the evaluation of classification and diagnostic
criteria that are considered in this review (Figure 1). Rele-
vant articles were defined as those that either illustrate dif-
ferences between classification criteria and diagnostic
criteria, identify key advantages and disadvantages of classi-
fication or diagnostic criteria, or evaluate performance char-
acteristics of classification or diagnostic criteria. Eighteen
additional relevant articles were identified through hand-
searching the bibliography of the initially identified 97
articles (Figure 1). Articles fit into one of the following 6 cat-
egories: 1) study of or commentary on differences and/or
similarities between classification criteria and physician
assessment, 2) description of the performance of classifica-
tion or diagnostic criteria in various populations, geographic
regions, or different practice settings, 3) proposal of original
or revised classification or diagnostic criteria, 4) comparison
of the performance of established classification criteria, 5)
description of various cohorts using established classifica-
tion criteria, and 6) discussion of either classification or
diagnostic criteria not otherwise related to one of the above
categories.
Summary of the published literature
1. Examples of the differential performance of classifica-
tion criteria in relation to physician assessment. No exam-
ples of direct comparison between diagnostic criteria and
classification criteria were identified in the literature
review. The performance of classification criteria as diag-
nostic tools has been assessed in a handful of studies.
Because of the lack of gold standards for diagnosis and
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classification, the performance of criteria sets was com-
pared with physician judgment in these studies. For exam-
ple, Rao et al assessed the measurement properties of the
1990 ACR classification criteria for vasculitis when used
as diagnostic criteria, relying on the treating rheumatolo-
gist’s final diagnosis as the gold standard (11). In that
study, only 38 (75%) of 51 patients with vasculitis fulfilled
the ACR classification criteria for one or more types of vas-
culitis, and 31 (21%) of 147 patients without vasculitis
also fulfilled these criteria (79% specificity). This illus-
trates that compared with a physician’s diagnosis, the
1990 ACR classification criteria had relatively low sensi-
tivity and specificity for predicting the presence of a spe-
cific type of vasculitis in an individual patient seen in
routine clinical practice. A separate study demonstrated
that the Chapel Hill Consensus Conference (CHCC) classi-
fication criteria for vasculitis correctly identified only 30%
of patients with the disease, when compared with a physi-
cian’s assessment (gold standard) (12). Likewise, Patarroyo
et al reported that 65.8% of patients with histopathologi-
cally proven vasculitis from a single center could not be
classified as having a discrete type of vasculitis as defined
by the CHCC criteria (13).
Clinicians have expressed concern about the high number
of patients in whom systemic lupus erythematosus (SLE) is
diagnosed in clinical practice who fail to meet the SLE clas-
sification criteria (14,15). Similarly, the diagnosis of knee
osteoarthritis (OA) made by community physicians is in
only fair agreement with the ACR criteria for the classifica-
tion of knee OA (k5 0.28) (16). Other examples of diseases
in which the classification criteria do not perform well
when compared with clinical diagnoses by treating rheuma-
tologists or experts include juvenile idiopathic arthritis and
systemic sclerosis (17–19). These examples may reflect not
only differences between physician decision-making versus
classification criteria but also that older classification crite-
ria may require revision; several criteria sets have now been
updated or are in the process of being updated (e.g., for rheu-
matoid arthritis [RA], systemic sclerosis [1,2]) or are being
developed (e.g., for vasculitis [20] and gout [21]).
Nonetheless, these examples suggest that classification
differs from diagnosis, and that use of classification crite-
ria may result in underreporting the presence of a disease.
This is because classification criteria capture a narrower
range of disease severity than that treated in routine clini-
cal practice, because classification criteria tend to identify
a uniform population for participation in clinical trials at
the expense of excluding some patients with less common
phenotypes, as suggested by the above-described exam-
ples (22). The rationale for perhaps favoring specificity
over sensitivity for classification criteria in the setting of
clinical trials is to avoid exposing patients who may not
have the disease to the possible risks associated with ex-
perimental interventions.
2. Need for revision of classification criteria. Newer
revised classification criteria may perform better than some
older classification criteria in terms of sensitivity and/or
specificity, with use of better data sets and methodology
(1,5,23). The more favorable risk–benefit profiles of therapeu-
tics and recognition that early therapy may affect long-term
prognosis have prompted trials in patients with rheumatic
diseases who do not yet meet the thresholds for traditional
classification. Consequently, some recent classification crite-
ria have focused more on improving the sensitivity of criteria
(1,23). For example, the notion that the ACR 1987 revised cri-
teria for the classification of RA (24) missed early disease
(i.e., lacked sensitivity) led to development of the ACR/Euro-
pean League Against Rheumatism 2010 criteria for RA (5)
(better sensitivity) so that patients with early disease could
be identified for intervention studies. It should be consid-
ered, however, that this approach may increase the chance of
false-positive results in the absence of gold standard tests
and likely has implications for prevalence estimates of these
diseases as well as for clinical practice. On the other hand, a
lack of sufficient specificity of criteria (i.e., false positives)
also has bearing on the enrollment of patients into trials of
agents with unclear safety/efficacy profiles; as a result, some
recent classification criteria have aimed to improve specific-
ity (21).
3. Effects of geographic area, practice setting, and
race on criteria performance. The performance of any cri-
teria (classification or diagnostic) is dependent on the prev-
alence of the disease in a given geographic area or clinical
setting (e.g., community clinic versus tertiary care facility).
While sensitivity and specificity are functions of the
screening test or criteria set and are not influenced by
disease incidence or prevalence, the predictive validity
Figure 1. Methods used for comprehensive literature search for
articles relevant to classification and/or diagnostic criteria.
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changes with the prevalence of the disease. The perform-
ance of criteria depends on both the pretest probability of
the disease, (which reflects the prevalence of the disease as
well as potential “mimickers”) and the sensitivity and spec-
ificity of the criteria themselves. Given the low prevalence
of certain rheumatologic diseases, the positive predictive
value (defined as the proportion of positive test results that
are true positives) of any criteria set will generally be low.
This is probably the reason why there are few diagnostic cri-
teria sets for rheumatology. For example, in areas where
Behc¸et’s disease is endemic (high pretest probability),
patients with recurrent oral ulcers may be accurately diag-
nosed and treated based on physician’s judgment in the
absence of supporting criteria, whereas in the US, where the
disease prevalence is low, any set of diagnostic criteria will
have a low positive predictive value. Similarly, the perform-
ance of the European Spondylarthropathy Study Group
(ESSG) preliminary criteria for the classification of spondy-
larthropathy varies across patients seen in private practices,
those seen at outpatient departments, and those admitted to
the hospital, depending on the prevalence of spondy-
loarthritis (SpA) in different regions (25). For example, in
Spanish rheumatology services where the prevalence of
SpA is 49%, the likelihood of a patient younger than age 35
years fulfilling the ESSG criteria for SpA is 87%. Conversely,
in clinics in France where the age-adjusted prevalence of
SpA is only 22.5%, the likelihood of fulfilling the ESSG cri-
teria is estimated to be 70% (25). While classification and
diagnostic criteria perform differently in different clinical
and geographic settings, this difference is less pronounced
for classification criteria, because their intended purpose is
to identify patients with similar disease features for studies
within different populations rather than to guide clinicians
in establishing diagnoses and making treatment decisions.
The same concept applies to patients of different races or
ethnicities within a geographic area. Indeed, the measure-
ment properties of classification criteria can differ markedly
when used in populations other than those used for develop-
ment of the classification criteria. As one example, a study
conducted in Asia showed that only 12 (17%) of 71 patients
with IgA vasculitis (Henoch-Sch€onlein) fulfilled both the
ACR vasculitis classification criteria and those of the CHCC
(26). The variable performance of both classification and
diagnostic criteria in different settings highlights the differ-
ences between these types of criteria and further illustrates
the difficulty of developing diagnostic criteria for which per-
formance is consistent across populations. Diagnostic crite-
ria will typically need to be based on the local prevalence of
the disease of interest as well as that of other diseases
included in the differential diagnosis, which is not practical
given the vast differences in epidemiology of most rheumatic
diseases in different clinical settings and geographic areas.
The performance of classification criteria is also affected by
their application to patients other than the intended target
population (e.g., if the 2010 criteria for the classification of
RA was applied to patients with “burned out” deforming
nodular RA, when it was intended for use in patients with
early active RA).
4. Well-defined disease phenotypes. One of the main
differences between classification and diagnostic criteria is
that classification criteria are aimed at assembling a study
sample that is well defined and representative of the vast
majority of patients with the disease. In contrast, diagnostic
criteria aim to identify all patients with the disease, including
those with unusual features or presentations. Achieving a rel-
atively homogeneous disease population is important for any
classification criteria so that multiple studies and popula-
tions can be compared or combined. On the other hand, to be
highly sensitive while preserving acceptable specificity, diag-
nostic criteria have to allow for all of the heterogeneous mani-
festations of the disease (which may be difficult to achieve in
rheumatic diseases). SLE is a prototypical example of a dis-
ease with heterogeneous presentations. Although the SLE
classification criteria can support a diagnosis of SLE, clini-
cians still must diagnose SLE based upon the totality of a
patient’s disease manifestations (27,28). Classification crite-
ria for SLE perform reasonably well for making a diagnosis in
academic medical centers that attract patients with more
severe or advanced disease, who typically have a higher pre-
test probability of having the diagnosis (27). However, the
SLE classification criteria may fail to recognize patients with
milder phenotypes or uncommon presentations of the
disease. Classification criteria tend to include phenotypic
features that have sufficiently high prevalence, whereas low-
prevalence features that may be very specific and helpful in
diagnosis are typically not included in criteria sets due to the
expected low yield from including such a feature.
5. Rheumatic diseases where both diagnostic and
classification criteria are feasible. Single sets of criteria
that serve for both classification and diagnosis appear feasible
for diseases for which there is a diagnostic “gold standard.”
The presence of monosodium urate crystals (MSU) in syno-
vial fluid during an episode of acute arthritis is widely con-
sidered diagnostic for gout. In fact, compared with the
presence of MSU crystals, the 1977 ACR preliminary criteria
for the classification of acute gout (29) have shown limited
diagnostic accuracy (30–32). In one study, diagnosis by pri-
mary care physicians correctly identified 93.5% of patients
with MSU crystal positivity, indicating that a clinician’s diag-
nosis of gout can be at least as sensitive as the classification
criteria for acute gout (30). Similar support for the use of diag-
nostic criteria can be applied to any rheumatic disease in
which the pathology is well understood and/or the etiology is
well defined. Infectious arthritides, such as septic arthritis,
can be diagnosed based on gold standard tests, and a diagnos-
tic criteria set can be devised. For such diseases, diagnostic
criteria are also suited to guiding subject identification for
research studies, because diagnostic criteria perform as well
as classification criteria in terms of sensitivity and specificity.
6. Resources and feasibility. Feasibility, acceptability,
and availability of resources are other potentially limiting
factors in establishing universally accepted diagnostic crite-
ria. Clinicians may be faced with limited access to or lack of
affordability of testing in certain geographic regions, patients’
own financial and/or insurance limitations, patient prefer-
ences, and overall health condition, among others, when
deciding on strategies to establish a diagnosis. This could
necessitate making a diagnosis and subsequently initiating
treatment based solely on a clinical basis. More stringent
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diagnostic criteria that require a particular laboratory or
imaging test or surgical procedure could constitute a hurdle
for patients and clinicians, and use of such criteria has the
potential to postpone the initiation of effective therapy.
7. Health priorities of a country or geographical area. In
a malaria-endemic area, a physician can empirically diag-
nose malaria in a patient with high-grade fever and chills
and start empiric treatment (9). In most cases, the initiation of
malaria treatment, without waiting for the results of a con-
firmatory test, prevents serious complications and even
death. The above clinical approach in these malaria-endemic
regions outweighs the harm of over-diagnosis and overtreat-
ment with a relatively nontoxic medication in patients with-
out malaria. Conversely, use of a similar approach in a
Nordic country would likely be unacceptable and irrational.
Therefore, the health priorities and conditions in different
countries/geographic areas often dictate the diagnostic
approaches to be used, which suggests that a single universal
diagnostic criteria set cannot always be applied equally in
different regions of the world. However, classification criteria
for the purpose of enrollment into clinical trials and epide-
miologic studies may be used across the globe, with high
specificity even if a few cases are missed, without affecting
the internal validity of the study.
8. Legal, financial, and treatment implications. Unlike
classification of a disease for research purposes, the accu-
rate diagnosis of a particular disease has important impli-
cations for a patient’s treatment as well as for billing and
reimbursement. Highly specific diagnostic criteria will
leave some patients undiagnosed (because no criteria will
ever be 100% sensitive). This means that such patients
may be denied treatment coverage if insurance companies
and government agencies use the diagnostic criteria as a
standard for reimbursement. Similarly, patients in whom
an illness was incorrectly diagnosed (because 100% speci-
ficity is difficult) can encounter difficulty in obtaining
health insurance or life insurance and may be exposed
unnecessarily to incorrect, potentially harmful, therapies.
9. Undifferentiated rheumatic diseases. Many patients
with rheumatic disease present to their physicians when
their disease is at an undifferentiated stage, which may later
evolve into more established disease. Although classifica-
tion criteria are typically applied at a given time point, they
can be reevaluated, because individuals may fulfill the crite-
ria as the disease manifestations change over time. Unlike
acute infection, many rheumatic diseases evolve over time,
and cross-sectional application of any criteria as either
“disease present or absent” is too simplistic. Moreover,
some cases may never evolve into well-established disease,
and others may transform from one presumed condition to
another. Strict universal diagnostic criteria may limit the
ability to make a clinical diagnosis and treat undifferenti-
ated diseases based on symptoms. This notion was empha-
sized in recent studies on the outcome of early arthritis, in
which 32–53% of patients remained unclassified after 1
year of observation (33,34). Similarly, in a 3-year followup
study of 270 patients with early arthritis, the diagnosis
remained unclear in 61 (23%) of the patients and changed
between the first and last examination in 96 (46%) of the
other 209 cases (35).
10. Complex decision making for diagnosis. Finally,
clinicians perform a complex multistep process in order
to make a diagnosis of rheumatic disease. This process
includes balancing the post-test probability of the dis-
ease with thresholds for further action based on factors
such as disease severity, risks of further testing, side
effects of treatment, and ruling out other conditions in
the differential diagnosis (e.g., infection or malignancy).
It is difficult to establish diagnostic criteria that may sat-
isfactorily perform this complex multistep process.
Role of the American College of Rheumatology
Classification criteria have demonstrated utility for identify-
ing well-defined, relatively homogeneous groups of patients
for clinical research purposes across different regions and
have some utility as teaching tools in the clinical setting;
however, they may not capture all physician-assigned diag-
noses. Conversely, compared with classification criteria,
diagnostic criteria appear to be more impacted by practice
setting, and the performance characteristics of diagnostic
criteria may vary significantly due to differences in disease
prevalence and the severity and manifestations of disease in
different settings. Given these differences, concerns regard-
ing the challenges in generating diagnostic criteria with con-
sistent performance properties, and the legal and financial
implications associated with diagnostic criteria, the ACR
will provide approval only for classification criteria and will
no longer consider funding or endorsing diagnostic criteria.
However, the ACR recognizes the importance of diagnostic
tools to aid rheumatologists in their clinical practice and
encourages their development. The ACR anticipates that
both types of criteria will continue to evolve as the pathoge-
nesis of rheumatic diseases becomes better understood and
as the emphasis on studies of comparative effectiveness
increases.
In conclusion, diagnostic and classification criteria play
central roles in clinical rheumatology practice. Unfortu-
nately, the existing criteria for rheumatic diseases are not
always properly applied, most often due to confusion
regarding the differences between the 2 types of criteria.
Classification criteria are used as a standardized means of
including a well-defined set of patients in research studies
to ensure comparability across studies. Given the heteroge-
neous nature of rheumatic diseases, it is difficult to capture
the full range of disease presentations using any single set of
criteria. Therefore, any criteria would be expected to fail to
identify some cases of a disease due to the criteria capturing
a more homogeneous population and a narrower range of
disease severity than that seen in routine clinical practice.
Nonetheless, classification criteria are critically important
for advancing research in the field of rheumatology, en-
abling the conduct of clinical trials and epidemiologic stud-
ies with well-defined patient populations. The process of
diagnosis, particularly for complicated multisystem involve-
ment typical of rheumatic diseases, is a highly complex cog-
nitive process that requires synthesis of many data points
typically beyond a simple algorithm-based set of criteria.
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